Skip to content

Application study of inhaled nitric oxide combined with prone ventilation in moderate to severe acute respiratory distress syndrome

Application study of inhaled nitric oxide combined with prone ventilation in acute respiratory distress syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085788
Enrollment
Unknown
Registered
2024-06-18
Start date
2025-01-03
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS

Interventions

Control Group:Prone position ventilation
Intervention Group:Nitric oxide inhalation combined with prone position ventilation

Sponsors

Subei People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged between 18 and 80 years old, with moderate to severe ARDS within 3 days of onset, meeting the 2012 Berlin diagnostic criteria, having an oxygenation index less than 150 mmHg, and undergoing mechanical ventilation via endotracheal intubation.

Exclusion criteria

Exclusion criteria: (1) Patients with severe asthma or acute exacerbation of chronic obstructive pulmonary disease, lung cancer, lung resection, and post-lung transplant surgery; (2) Patients with hemodynamic instability requiring vasoactive drugs for maintenance: using dopamine, dobutamine > 15µg/kg/min, norepinephrine > 0.3ug/kg/min; (3) Cardiogenic pulmonary edema; (4) Patients with severe facial deformities, facial trauma, or severe chest and abdominal trauma who are unable to undergo prone position ventilation; (5) Patients in the middle to late stages of pregnancy; (6) Patients with a history of malignant tumors or other irreversible diseases/conditions, terminal patients; (7) Patients expected to be discharged shortly or receiving invasive mechanical ventilation for less than 24 hours; (8) Patients currently participating in other studies. The experimental protocol has been approved by the ethics committee, and the patients or their authorized representatives have signed the informed consent form.

Design outcomes

Primary

MeasureTime frame
PaO2/FiO2;

Secondary

MeasureTime frame
ventilator free days druing 28 days;ICU hospitalization time;28 day mortality rate;

Countries

China

Contacts

Public ContactXiaoyan Wu

Subei People's Hospital

ntywxy@163.com+86 180 5106 0663

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026